CTLA4 and melanoma: Combinatorial therapy of anti-CTLA-4 and anti-PD-L1 blockade displayed more evident tumor regression in approximately 50% of patients with advanced melanoma, in some cases, more than 80% of total patients were presented with disease remission and long-term free survival (42, 43).